Spain has just redrawn the rules of health technology assessment

Spain has just redrawn the rules of health technology assessment. Here is what it means for market access.

This week, the Spanish Council of Ministers approved the Royal Decree on Health Technology Assessment, creating Spain’s first formal, coordinated framework for assessing health technologies across the National Health System.

And this is not only about medicines.

The new framework can cover medicines, medical devices, diagnostic tests, clinical and surgical procedures, digital therapeutics, and even new models of care such as remote patient monitoring or home-based care.

A few things stand out.

• Assessments become mandatory, but not binding. Technologies within scope will be evaluated to inform decisions on funding, pricing, inclusion in the service portfolio, changes in conditions of use or withdrawal. But the assessment itself does not dictate the decision. Scientific evaluation and policy decision-making remain separate.

• Spain will no longer duplicate EU-level clinical assessments. Where a Joint Clinical Assessment already exists at European level, Spain will not repeat the clinical work. The national focus moves to what is genuinely local: added value in the Spanish context, budget impact, organisational feasibility, and the ethical, social, legal and environmental dimensions of adoption.

• There are clearer timelines. The headline is a maximum evaluation window of up to 180 days, with a fast national clinical step when a European Joint Clinical Assessment already exists. That brings more predictability, although the real test will be whether the system has the capacity to meet these timelines in practice.

• Early dialogue becomes more relevant. Companies will be able to request voluntary scientific consultations before market entry. For market access teams, this may become one of the most important strategic tools in the new framework: a chance to align evidence generation with what the Spanish system will actually need to see.

• Evidence will not stop at launch. The decree reinforces the use of real-world data, periodic reassessment and the possibility of recommending disinvestment when a technology no longer demonstrates sufficient value versus available alternatives.

So what changes for those of us working in market access?

The centre of gravity moves earlier.

If the clinical evidence package is increasingly shaped at European level, the winning value story in Spain will be the local one. Budget impact, implementation burden, care pathway fit, patient relevance, regional adoption and real-world evidence will matter more, not less.

Predictability is the headline. Execution is the catch.

Clear timelines are helpful, but this is not an overnight switch. Methodological guidance still needs to be developed, implementation will be progressive, and the assessment remains separate from the final pricing and funding decision.

For pharmaceutical companies, the implication is clear: Spanish access strategy cannot be built at the end of the regulatory process. It needs to be designed earlier, with the right evidence, the right local comparators, the right budget narrative and a credible lifecycle plan.

Spain has moved closer to the more structured HTA systems in Europe.

The opportunity is not simply to react to the new framework.

It is to prepare before it fully switches on.

Strategic implication for Acumetis clients

• Start Spanish access strategy earlier, before regulatory approval or national submission.
• Use early dialogue to stress-test local evidence needs and expected payer questions.
• Build Spain-specific value narratives around budget impact, implementation and real-world evidence.
• Treat launch evidence as the start of a lifecycle evidence plan, not a one-off dossier exercise.